119 related articles for article (PubMed ID: 35839046)
1. PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in cutaneous angiosarcoma: A case report.
Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Tanaka H; Ohtani K; Kakinoki R; Akagi M
Medicine (Baltimore); 2022 Jul; 101(28):e29621. PubMed ID: 35839046
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas.
Hashimoto K; Nishimura S; Ito T; Kakinoki R; Akagi M
Eur J Histochem; 2022 Apr; 66(2):. PubMed ID: 35448937
[TBL] [Abstract][Full Text] [Related]
3. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
Ren Y; Lv Q; Yue W; Liu B; Zou Z
Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
6. Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma.
Kawamura A; Kawamura T; Riddell M; Hikita T; Yanagi T; Umemura H; Nakayama M
Cancer Sci; 2019 May; 110(5):1780-1789. PubMed ID: 30801864
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma.
Bi Y; Ge L; Ren X; Pang J; Zhao Y; Liang Z
Clin Transl Oncol; 2022 May; 24(5):941-949. PubMed ID: 35064455
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
Guo W; Zhang F; Shao F; Wang P; Li Z; Yang X; He Z; Shi S; Gao Y; He J
Hum Pathol; 2019 Feb; 84():291-298. PubMed ID: 30296523
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression in Cutaneous Angiosarcomas: A Systematic Review with Meta-Analysis.
Lobrano R; Paliogiannis P; Zinellu A; Palmieri G; Persico I; Mangoni AA; Cossu A
Curr Oncol; 2023 May; 30(5):5135-5144. PubMed ID: 37232846
[TBL] [Abstract][Full Text] [Related]
12. Antiprogrammed cell death protein 1 immunotherapy for angiosarcoma with high programmed death-ligand 1 expression: a case report.
Xu F; Zheng J; Fu M; Zhou H
Immunotherapy; 2020 Aug; 12(11):771-776. PubMed ID: 32611263
[No Abstract] [Full Text] [Related]
13. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
14. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
Akutsu Y; Murakami K; Kano M; Toyozumi T; Matsumoto Y; Takahashi M; Otsuka R; Sekino N; Yokoyama M; Shiraishi T; Matsubara H
Esophagus; 2018 Apr; 15(2):103-108. PubMed ID: 29892935
[TBL] [Abstract][Full Text] [Related]
15. MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases.
Kerkar SP; Wang ZF; Lasota J; Park T; Patel K; Groh E; Rosenberg SA; Miettinen MM
J Immunother; 2016 May; 39(4):181-7. PubMed ID: 27070449
[TBL] [Abstract][Full Text] [Related]
16. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.
Okadome K; Baba Y; Yasuda-Yoshihara N; Nomoto D; Yagi T; Toihata T; Ogawa K; Sawayama H; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
Cancer Sci; 2022 Feb; 113(2):399-410. PubMed ID: 34773342
[TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.
Kim R; Keam B; Kwon D; Ock CY; Kim M; Kim TM; Kim HJ; Jeon YK; Park IK; Kang CH; Kim DW; Kim YT; Heo DS
World J Gastroenterol; 2016 Oct; 22(37):8389-8397. PubMed ID: 27729745
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression.
Hou Z; Liang X; Wang X; Zhou Z; Shi G
Oncol Lett; 2020 Jun; 19(6):3982-3992. PubMed ID: 32382343
[TBL] [Abstract][Full Text] [Related]
20. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
